Cannabis Genotyping Pipeline

格林威温室大麻公司(Greenway)是一家垂直整合的药用大麻生产商**，最近从其母公司Sunite温室有限公司剥离出来，该公司在商业园艺方面拥有超过45年的**经验和超过400万平方英尺的水培生产面积(50万平方米)。英国《金融时报》其中一部分是献给Greenway的)。Greenway还可以获得多样化和独特的种质**(即种子和组织)资源，包括由专家育种者合法赠送作为种子**的100个高价值大麻菌株的集合。尽管Greenway拥有丰富的园艺专业知识和基础设施，但它在遗传学方面缺乏**研究能力，因此寻求学术合作伙伴合作开发一种新颖的、**快速的系统来确定其种质的遗传特征。这将使Greenway能够合理地选择其菌株的**子集，用于进一步的开发、育种和商业化。这也将为关键性状的遗传图谱、品种保护和质量保证**奠定基础。**为了实现合作目标，开发一种快速、基于DNA的方法来确定大麻菌株的**相关性，我们将利用**1300个大麻菌株的DNA序列信息，并识别一组384个遗传标记(SNP，单核苷酸多态)，**将用于通过测序进行基因分型分析，以产生每个菌株的遗传指纹。这些遗传指纹将从100个高价值菌株和已知菌株中获得，以鉴定**相关种质群。这些集群还将与收集的关于每个菌株的生长和(在**未来)化学性质的信息进行比较。将**确定信息性标记的最小数量，以在未来进一步简化议定书。这些结果将构成未来**合作的基础，包括发展多样化的育种和绘制种群图。

Greenway Greenhouse Cannabis Corporation (Greenway) is a vertically integrated medicinal cannabis**producer, recently spun off from its parent company, Sunrite Greenhouses Ltd., which has over 45 years of**experience in commercial horticulture and over 4 million square feet of hydroponic production area (0.5**million sq. ft. of this is dedicated to Greenway). Greenway also has access to diverse and unique germplasm**(i.e. seed and tissue) resources, including a collection of 100 high-value cannabis strains gifted legally as seeds**by an expert breeder. Although Greenway has substantial horticultural expertise and infrastructure, it lacks**research capacity in genetics and therefore seeks an academic partner to collaborate on development of a novel,**rapid system for genetically characterizing its germplasm. This will allow Greenway to rationally select a**subset of its strains for further development, breeding, and commercialization. This will also lay a foundation**for genetic mapping of key traits, variety protection, and quality assurance.**To accomplish the collaborative objective of developing a rapid, DNA-based method for defining the**relatedness of cannabis strains, we will leverage DNA sequence information already in the public domain for**1300 cannabis strains, and identify a set of 384 genetic markers (SNPs, single-nucleotide polymorphisms) that**will be used in a genotyping-by-sequencing assay to produce genetic fingerprints for each strain. These genetic**fingerprints will be obtained for the 100 high-value strains and from known strains, to identify clusters of**related germplasm. These clusters will also be compared to information collected about the growth and (in the**future) the chemical properties of each strain. The minimum number of informative markers will be**determined to further streamline the protocol in the future. These results will form the basis of future**collaborations including development of diverse breeding and mapping populations.